The new Dual-Color Assays accelerate the pace and expand the biological space in the quest to discover new autoantibody biomarkers.
The Dual-Color IgG/IgA Assays enable the simultaneous and sensitive detection of IgG and IgA autoantibodies with exquisite specificity from very low sample volume input.
Dual-Color Assays Services are now available with all Sengenics protein arrays, which are based on the patented KREX protein folding technology and are designed for highly specific and reproducible discovery of autoantibody biomarkers.
The Dual-Color Assays are powered by expert bioinformatic and machine learning-based data analysis services, leading to the identification of biomarker signatures.
The new Dual-Color Assay Services expand the view of disease biology and accelerate autoantibody biomarker discovery across the autoimmune disease, immuno-oncology and neuroinflammation fields.
The Dual Color IgG/IgA Assay Services expands Sengenics' systems serology tools enabling a deeper dive into the humoral immune response.
Sengenics is a precision medicine company working to improve patient outcomes through physiologically relevant, data-guided decision making.
Its solutions enable the discovery and validation of autoantibody biomarker signatures for patient stratification, therapeutic response prediction and development of companion diagnostics.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial